Medtronic (NYSE:MDT) subsidiary Medtronic Canada said today that it landed a license with Health Canada for its MiniMed 630G insulin pump system for patients with diabetes mellitus.
The Fridley, Minn.-based company said it interviewed more than 1,000 diabetes patients to better understand the features they look for in an insulin pump. The final product has a user-friendly pump that is waterproof in up to 12 feet of water for a maximum of 24 hours and features a high-definition screen.
The 630G system integrates continuous glucose monitoring and the company’s SmartGuard tech, which triggers an alarm when the sensor reaches a preset low limit. If the user in unresponsive to the alarm, the device will suspend insulin delivery. The SmartGuard features are the 1st of its kind in Canada, according to Medtronic.
“We are excited to announce the launch of the MiniMed 630G system for Canadians living with diabetes,” director of diabetes & consumer care, Laura Cameron, said in prepared remarks. “This latest innovation is a step towards Medtronic’s vision of transforming diabetes care and our commitment to providing improved outcomes and an improved user experience for our customers.”
The device will be commercially available in Canada in early 2017. Medtronic announced the US launch of the MiniMed 630G in August and recently won FDA approval for the 1st artificial pancreas.
